View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 11, 2022

Pliant reports positive data from Phase IIa idiopathic pulmonary fibrosis trial

In the trial, PLN-74809 was found to be well tolerated at all three tested dose levels.

Pliant Therapeutics has reported positive findings from the Phase IIa INTEGRIS-IPF clinical trial of the new investigational therapy, PLN-74809, to treat idiopathic pulmonary fibrosis (IPF) patients.

The multinational, double-blind, randomised, placebo-controlled trial analysed 40mg, 80mg and 160mg once-a-day doses of PLN-74809 versus placebo for 12 weeks.

It enrolled a total of 90 subjects with 67 in the active arms and 23 patients in the placebo arm.

Nearly 80% of trial subjects enrolled received standard of care and were split equally between nintedanib and pirfenidone.

Assessing the safety and tolerability of PLN-74809 was the trial’s primary endpoint while evaluation of pharmacokinetics was the secondary endpoint.

According to the findings, the trial met the primary and secondary endpoints.

PLN-74809 was found to be well tolerated at all three tested dose levels without any deaths or drug-associated serious adverse events (SAE) observed.

Furthermore, the therapy showed dose-proportional rises in plasma concentrations, in line with previous trials.

The trial’s exploratory endpoints assessed variations in forced vital capacity (FVC), high-resolution CT (HRCT)-based quantitative lung fibrosis (QLF) and serum biomarkers over 12 weeks of treatment.

Dose-proportional treatment effects on FVC and QLF compared to placebo were reported over 12 weeks.

Subject enrolment in the 320mg cohort of the trial concluded recently with 12-week interim data from this cohort anticipated earlier next year.

The company plans to submit the latest data to regulatory authorities soon to hold talks on the late-stage development of PLN-74809.

Pliant Therapeutics chief medical offer Éric Lefebvre said: “Data from the INTEGRIS-IPF trial exceeded our expectations exhibiting a favourable safety and tolerability profile and a treatment effect on FVC, the current registrational endpoint in IPF. 

“Additionally, the dose-dependent reduction observed in the proportion of patients experiencing a decline in percent predicted FVC of ≥10% underscores the potential of this novel investigational therapy to advance the treatment of IPF.”

A chronic and progressive fibrosing lung disease of unknown cause, IPF has a reduced prognosis and less treatment options.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena